CClinicalTrials.gg
Sign In
RecruitingNCT07698743TCA-PKUUpdated Jul 13, 2026

Eating Disorders in Patients With Phenylketonuria

An observational study in Phenylketonuria, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Central Hospital, Nancy, France · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Sex
All
01

Study summary

The prevalence of eating disorders and BMI are significantly higher in PKU patients than in the general population. The protein-restricted diet associated with high carbohydrate intake and the severity of the genetic defect and disease can lead to weight gain in these patients; However, the link between restrictive diets, EDs, and obesity has not been demonstrated in patients with PKU. These issues remain poorly explored, meaning that patients may not be detected and treated.

02

Conditions studied

  • Phenylketonuria

Browse trials for

03

In context

Phenylketonurias

183 studies on the registry are indexed under Phenylketonurias; 38 are open to participants now.

This study's planned enrollment of 70 is above the median of 40 across 60 observational studies indexed under Phenylketonurias.

Browse Phenylketonurias studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects followed for PKU at Nancy University Hospital

Inclusion criteria

  • Subjects followed for PKU at Nancy University Hospital
  • Subjects willing to participate

Exclusion criteria

Exclusion Criteria:

  • Subjects not villing to participate
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Phenotypes related to TCA in the PCU cohort of the Reference Center for Hereditary Metabolic Diseases

    Time frame: from january 2026 to january 2028

07

Study locations

1 of 1 sites recruiting
  • CHRU de Nancy
    Nancy, 54000, France
    Recruiting
08

References and documents

Publications

  • van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Beblo S, Blau N, Bosch AM, Burlina A, Campistol J, Coskun T, Feillet F, Gizewska M, Huijbregts SC, Leuzzi V, Maillot F, Muntau AC, Rocha JC, Romani C, Trefz F, van Spronsen FJ. European guidelines on diagnosis and treatment of phenylketonuria: First revision. Mol Genet Metab. 2025 Jun;145(2):109125. doi: 10.1016/j.ymgme.2025.109125. Epub 2025 Apr 30. PubMed 40378670 ↗

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698743
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Dec 4, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Apr 2, 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Eva Feigerlova, MD PhD MMEd
Contact
e.feigerlova@chru-nancy.fr
+330383154796

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Phenylketonurias→

Other studies from this sponsor

Central Hospital, Nancy, France

Start the discussion